Medical/Pharmaceuticals
Alterity to present at the 7th International Congress of Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format fromFebruary 26-...
2021-02-26 20:45
6314
Tigermed Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine as Clinical Contract Research Organization
HANGZHOU, China, Feb. 26, 2021 /PRNewswire/ -- China National Medical Products Administration (NMPA) announced onFebruary 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (the "Ad5-nCoV", trade name: Convidecia™). CanSino Biologics Inc. an...
2021-02-26 16:36
5242
ARANZ Medical's Silhouette® system becomes a national platform for wound telehealth assessments
CHRISTCHURCH, New Zealand, Feb. 25, 2021 /PRNewswire/ -- The US Department of
Veteran's Affairs (VA) is establishingARANZ Medical's Silhouette solution as a
VA national platform, enabling more VA Medical Centers to utilize Silhouette in
their wound telehealth programs.
2021-02-26 09:39
1492
Biocytogen announces acquisition of a third Beacon Optofluidic system to support expanding Antibody Discovery Platform
BOSTON, Feb. 25, 2021 /PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen's antibody discove...
2021-02-25 23:45
1743
I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., Feb. 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in the phase 3 piv...
2021-02-25 21:00
4906
Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients
SEOUL, South Korea, Feb. 24, 2021 /PRNewswire/ -- Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading immuno-oncology firm, and Debiopharm, a Swiss-based biopharmaceutical company specializing in oncology and infectious diseases, today announced having entered into a research ...
2021-02-25 07:00
2253
I-Mab Announces Upcoming Participation at March Conferences
SHANGHAI and GAITHERSBURG, Md., Feb. 24, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in March....
2021-02-24 21:00
4824
WuXi Diagnostics Secures US$150 Million Series B Financing to Accelerate Market Penetration in Global Diagnostics Sector
SHANGHAI, Feb. 23, 2021 /PRNewswire/ -- WuXi Diagnostic Investment (Cayman) Limited ("WuXi Diagnostics") announced that it has completedUS$150 million in series B funding, joined by new investors including Thermo Fisher Scientific Inc. ("Thermo Fisher"), Shiyu Capital ("SHIYU"), ABC International...
2021-02-24 08:00
2412
Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.
TOKYO, Feb. 23, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS). HOS specializes in predictive analytics and clinical decision support that enable healthcare...
2021-02-24 07:00
8587
Gracell Biotechnologies to Report Fourth Quarter and Fiscal 2020 Financial Results on Tuesday, March 9, 2021
SUZHOU and SHANGHAI, China, Feb. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it plans to release ...
2021-02-23 21:00
7961
Curocell announces Korean FDA clearance of the IND for CRC01, a first in kind immune checkpoint receptors downregulated CD19 CAR-T therapy
DAEJEON, South Korea, Feb. 22, 2021 /PRNewswire/ -- Curocell, Inc., a clinical-stage biotech developing next-generation CAR-T (OVIS™) therapies, announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved its Phase 1/2 clinical study application forCRC01, CD19 CAR-T cell the...
2021-02-22 22:00
1393
Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial
* BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase2b PTSD trial * BNC210 Phase 2b PTSD trial on target for start in mid-2021 with final dose selected ADELAIDE, Australia, Feb. 22, 2021 /PRNewswire/ -- Bionomics Limited (ASX: B...
2021-02-22 19:00
3241
Completion of Patients' Recruitment for Proxalutamide's COVID-19 Hospitalised Study
SUZHOU, China, Feb.22, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the clinical trial of Proxalutamide for the treatment of hospitalised COVID-19 patients inBrazil completed the recruitment of 588 patients. The data of the clinical trial is expected ...
2021-02-22 17:14
3221
China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split
TAIZHOU, China, Feb. 19, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Ad...
2021-02-19 21:00
5744
Psychobiotic PS128 consumption shows benefits to Parkinson's symptoms in new clinical study
TAIPEI, Feb. 18, 2021 /PRNewswire/ -- Bened Biomedical, a leading Taiwanese probiotic company, has announced a successful clinical study for its PS128 psychobiotic in treating symptoms of Parkinson's disease (PD). The study was led by a neurologist, Dr.Chin-Song Lu, a renowned researcher for PD i...
2021-02-19 12:07
1789
GenScript ProBio and Neoletix Announce Successful Completion of 200-Liter GMP Production Runs of Recombinant Coagulation FVIII Based on a Novel Production Technology
NANJING, China, Feb. 18, 2021 /PRNewswire/ -- On February 7th, 2021, GenScript ProBio announced that it has successfully completed 3 X 200 L GMP production runs of recombinant human factor VIII (rhFVIII) for Beijing Neoletix Biological Technology Co., Ltd. (Neoletix). InMay 2019, GenScript ProBio...
2021-02-18 22:00
1931
United Imaging Announces Agreement with Vizient for Computed Tomography Systems.
HOUSTON, Feb. 18, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced an agreement to offer its suite of cutting-edge Computed Tomography technology to Vizient members at contracted pricing. For maximum clinical flexibility, all ...
2021-02-18 21:00
1835
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer
SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Everest Medicines
2021-02-18 12:21
3594
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD
ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF,Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly owned subsidiary ofGermany-based CNS clinical development...
2021-02-17 19:00
5974
Bionic Vision Technologies Advances Clinical Program With AU$1 million Medical Research Future Fund Grant
MELBOURNE, Australia, Feb. 16, 2021 /PRNewswire/ -- Bionic Vision Technologies (BVT) has started work on the next phase of development for its world-leading Australian bionic eye technology thanks to a recent Australian Government grant to refine its vision processing algorithms. BVT's bionic ey...
2021-02-17 08:03
1385
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 300 media titles]
2025-01-23 09:00
Infobip Research Unveils Opportunities for Brands to Engage Customers with Rich Communication Services (RCS) across APAC
[Picked up by 291 media titles]
2025-01-20 21:09
Most Read
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
6428
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
2025-01-20 14:27
4908
Premium Features, Budget Price: Don't Miss the Fossibot S3 Pro's Dual-Screen AMOLED Debut
2025-01-19 15:00
4400
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
2025-01-22 15:38
4275
TikTok "Refugees" Flock to U.S. Owned Rival, Triller
2025-01-19 03:53
4070